



# An efficient system for the Pd-catalyzed cross-coupling of amides and aryl chlorides

Brett P. Fors, Karin Dooleweerd, Qingle Zeng, Stephen L. Buchwald\*

Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, United States

## ARTICLE INFO

### Article history:

Received 19 March 2009

Received in revised form 28 April 2009

Accepted 29 April 2009

Available online 8 May 2009

This paper is dedicated to Larry Overman on the occasion of his receipt of the 2008 Tetrahedron Prize in Organic Chemistry

### Keywords:

Palladium

Phosphine

Cross-Coupling

Amidation

## ABSTRACT

A catalyst based on a new biarylphosphine ligand (**3**) for the Pd-catalyzed cross-coupling reactions of amides and aryl chlorides is described. This system shows the highest turnover frequencies reported to date for these reactions, especially for aryl chloride substrates bearing an *ortho* substituent. An array of amides and aryl chlorides were successfully reacted in good to excellent yields.

© 2009 Elsevier Ltd. All rights reserved.

## 1. Introduction

Metal-catalyzed amidation reactions of aryl halides or pseudo halides are an attractive method for synthesizing *N*-arylamides. These reactions were traditionally performed with aryl iodides under Goldberg-modified Ullman cross-coupling conditions using stoichiometric Cu and high reaction temperatures.<sup>1</sup> Recent advances in this area have allowed for the reactions of amides and aryl iodides or aryl bromides to be performed using catalytic amounts of Cu under milder conditions.<sup>2</sup> Pd-based catalyst systems using phosphine ligands have also been developed, which allow for the coupling of amides with aryl sulfonates,<sup>3</sup> aryl bromides,<sup>4</sup> and most recently, aryl chlorides.<sup>5</sup> These methods have proven to be useful to synthetic chemists and have been widely used in both industrial and academic laboratories.<sup>6</sup>

Of the aryl halides, aryl chlorides are generally the most attractive substrates for cross-coupling reactions because they are less expensive and more readily available. Our group previously reported a catalyst system, based on ligand **1** (Fig. 1), that effectively promoted the cross-coupling of amides and unhindered aryl chlorides,<sup>5a</sup> but was less effective with *ortho*-substituted aryl chlorides. Mechanistic studies and DFT calculations indicated to us

that the methyl substituent *ortho* to the di-*tert*-butylphosphino group in ligand **1** prohibited rotation around the P-C<sub>Ar</sub> bond, forcing the Pd(II) center of the resulting oxidative addition complex to position itself over the non-phosphine-containing ring (Fig. 2). It was postulated that this conformation inhibited the formation of the  $\kappa^2$ -amidate complex, accelerating reductive elimination. On the other hand, DFT calculations have also indicated that the amine binding step of the catalytic cycle using biarylphosphine ligands is slower when the Pd(II) is positioned over the non-phosphine containing ring.<sup>7</sup> Having an *ortho* substituent on the arene in these complexes compounds this effect by increasing the crowding around the Pd(II) center, hence, further slowing 'transmetalation' (amide binding/deprotonation). Herein, we report a catalyst system, which displays high activity for the amidation of aryl chlorides, including those with *ortho* substitution, by facilitating transmetalation while still inhibiting the formation of a  $\kappa^2$ -amidate intermediate.

## 2. Results and discussion

### 2.1. Optimization of the Pd-catalyzed amidation reactions of aryl chlorides

Our group recently disclosed a catalyst system, based on **2**, that was highly active and selective for the monoarylation of primary

\* Corresponding author. Tel.: +1 617 253 1885; fax: +1 617 253 3297.

E-mail address: [sbuchwal@mit.edu](mailto:sbuchwal@mit.edu) (S.L. Buchwald).




Figure 1. Biarylphosphine ligands.




Figure 2. Pd(II) oxidative addition complex based on ligand 1.


amines.<sup>8</sup> In this study we observed that, in solution, the oxidative addition complexes of **2** existed as two rotamers; for one of which the environment around the Pd center was less sterically demanding. We hypothesized that the substitution of a methoxy substituent *ortho* to the di-*tert*-butylphosphino group in **1** (see ligand **3**) would allow for more freedom of rotation around the P–C<sub>Ar</sub> bond and help promote transmetalation with relatively hindered substrates. This new ligand (**3**) was easily synthesized in two steps from commercially available starting materials (see [Experimental](#) section).

Initial studies employing the supporting ligand **3** focused on the coupling of acetamide and 2-chlorotoluene in the presence of various Pd sources, bases, and solvents. We found that when the catalyst was formed using our recently reported water-mediated catalyst preactivation method<sup>9</sup> with **3**, Pd(OAc)<sub>2</sub>, and K<sub>3</sub>PO<sub>4</sub> as the base in *t*-BuOH, the reaction gave a 99% GC yield after 40 min at 110 °C ([Table 1](#), entry 1). This initial result was very promising as it represented the highest turnover frequency observed to date for the Pd-catalyzed amidation reactions of aryl chlorides bearing an *ortho* substituent.<sup>5a</sup> Switching the Pd source to Pd<sub>2</sub>(dba)<sub>3</sub> or Pd(dba)<sub>2</sub> resulted in a dramatic reduction in yield ([Table 1](#), entries 2 and 3). This loss of activity is likely caused by coordination of the

dba ligands to the Pd, which is a well known effect of dba in cross-coupling reactions.<sup>10</sup> The use of Pd(II) salts (e.g., [(allyl)PdCl]<sub>2</sub>, (H<sub>3</sub>CCN)<sub>2</sub>PdCl<sub>2</sub>, or Pd(OAc)<sub>2</sub>) without preactivation, all of which need to be reduced quickly and efficiently in order to generate an active catalyst, leads to yields below 60%.<sup>11</sup> These results demonstrated the importance of forming the active monoligated Pd(0) complex in these reactions. The use of carbonate bases showed similar results for this coupling reaction,<sup>12</sup> but a substantial decline in yield was observed with all bases examined when other common solvents were used ([Table 1](#), entries 9 and 10).


## 2.2. Comparison of ligands for the Pd-catalyzed amidation reactions of aryl chlorides

Encouraged by our initial results, we set out to compare reactions with ligand **3** directly with those employing other biarylphosphine ligands that had previously been used for Pd-catalyzed amidation reactions. Using a catalyst based on **1** for the cross-coupling of acetamide and 2-chlorotoluene resulted in a 12% yield (GC), whereas using a catalyst supported by **3** afforded the product in a 99% yield ([Fig. 3](#)). This result demonstrates that changing the substituent *ortho* to the di-*tert*-butylphosphino group in **1** from a methyl to a methoxy group, as in **3**, has a dramatic effect on the activity of these systems. We believe this increase in activity is due to the increased freedom of rotation around the P–C<sub>Ar</sub> bond in **3**, which may accelerate transmetalation. With **2**, the dicyclohexylphosphino analogue of **3**, a 65% yield of product was realized. With



**Table 1**  
Screen of reaction parameters for the cross-coupling of acetamide and 2-chlorotoluene

Entry	Pd Source	Base	Solvent	Yield (%)
1	Pd(OAc) <sub>2</sub> /H <sub>2</sub> O Act.	K <sub>3</sub> PO <sub>4</sub>	<i>t</i> -BuOH	99
2	Pd <sub>2</sub> (dba) <sub>3</sub>	K <sub>3</sub> PO <sub>4</sub>	<i>t</i> -BuOH	27
3	Pd(dba) <sub>2</sub>	K <sub>3</sub> PO <sub>4</sub>	<i>t</i> -BuOH	25
4	[(allyl)PdCl] <sub>2</sub>	K <sub>3</sub> PO <sub>4</sub>	<i>t</i> -BuOH	48
5	(H <sub>3</sub> CCN) <sub>2</sub> PdCl <sub>2</sub>	K <sub>3</sub> PO <sub>4</sub>	<i>t</i> -BuOH	46
6	Pd(OAc) <sub>2</sub>	K <sub>3</sub> PO <sub>4</sub>	<i>t</i> -BuOH	57
7	Pd(OAc) <sub>2</sub> /H <sub>2</sub> O Act.	CS <sub>2</sub> CO <sub>3</sub>	<i>t</i> -BuOH	99
8	Pd(OAc) <sub>2</sub> /H <sub>2</sub> O Act.	K <sub>2</sub> CO <sub>3</sub>	<i>t</i> -BuOH	96
9	Pd(OAc) <sub>2</sub> /H <sub>2</sub> O Act.	K <sub>3</sub> PO <sub>4</sub>	Toluene	10
10	Pd(OAc) <sub>2</sub> /H <sub>2</sub> O Act.	K <sub>3</sub> PO <sub>4</sub>	1,4-Dioxane	0



**Figure 3.** Results observed for the coupling of acetamide and 2-chlorotoluene with various ligands.

**Table 2**  
Pd-catalyzed cross-coupling of amides and aryl chlorides<sup>a</sup>

















































Entry	ArCl	Amide	Product	Time	Yield <sup>b</sup> (%)
1				40 min	83
2				1.5 h	78
3				3 h	91
4				3 h	93
5				1.5 h	92
6				2 h	80
7				5 h	83
8				2 h	98
9				3 h	85
10				1.5 h	90
11				3 h	84
12				1.5 h	96
13				5 h	90
14				4 h	70

Table 2 (continued)

Entry	ArCl	Amide	Product	Time	Yield <sup>b</sup> (%)
15				12 h	61
16				1.5 h	93

<sup>a</sup> Reaction conditions: ArCl (1.0 equiv), amide (1.2 equiv), K<sub>3</sub>PO<sub>4</sub> (1.4 equiv), Pd(OAc)<sub>2</sub> (1 mol %), **3** (2.2 mol %), H<sub>2</sub>O (4 mol %), *t*-BuOH (2 mL/mmol), 110 °C.

<sup>b</sup> Isolated yields, average of two runs.

the ligand lacking the two methoxy substituents, *t*-BuXPhos (**4**), only a 15% yield of the desired product was formed.<sup>5a,13</sup> These results reveal that both the methoxy group *ortho* to the di-*tert*-butylphosphino group and the di-*tert*-butyl groups on the phosphorus center in **3** are important to the high activity observed when this ligand is employed. Finally, with ligand **5** (XPhos), which had previously been reported to be suitable ligand for Pd-catalyzed amidation reactions of aryl tosylates, only a trace of product was observed.<sup>3e</sup>

### 2.3. Substrate scope for the Pd-catalyzed amidation reactions of aryl chlorides using a catalyst system based on ligand **3**

We next explored the scope of the Pd-catalyzed cross-coupling reactions of aryl chlorides and amides with our new catalyst system. We began by examining the effect of the *ortho* substituent on the aryl chloride. As we had already observed, 2-chlorotoluene was successfully coupled with acetamide in high yield (Table 2, entry 1). When the methyl substituent was replaced with the larger ethyl group the coupling still proceeded in good yield (Table 2, entry 2). When the *ortho* substituent was changed to an electron-donating methoxy group the rate of the coupling decreased slightly, the reaction took 3 h to proceed to completion, but still gave 91% of the desired product (Table 2, entry 3). Aryl chlorides with *ortho* substitution were also coupled with benzamide in excellent yields (Table 2, entries 4 and 5). These examples show the superior reactivity of this system over previously reported catalysts. Unfortunately, the reactions of aryl chlorides with two *ortho* substituents failed to provide product under these conditions.

We next examined the reactions of aryl chlorides that lacked an *ortho* substituent. Utilizing **3** as the ligand, the reaction of 4-chlorotoluene with 4-trifluoromethylbenzamide gave the desired product in good yield with 1 mol % Pd in only 2 h (Table 2, entry 6). The reactions of similar substrates with the best previously reported catalyst system required times between 12 and 24 h.<sup>5a</sup>

Due to the ubiquity of heterocycles in many biologically active molecules, we next wanted to extend the scope of this system to heteroaryl substrates. Amides containing furans, pyridines, and thiophenes were all well tolerated in these reactions. These could be successfully coupled with a variety of aryl chlorides in good to excellent yields, all with reaction times that were <5 h using 1 mol % Pd (Table 2, entries 8–14). For example, the coupling of furan-2-carboxamide with 2-chloroanisole gave a 98% yield of the desired product in 2 h (Table 2, entry 8). Additionally, a heteroaryl chloride, 3-chloropyridine, was also an excellent coupling partner for this reaction (Table 2, entries 15 and 16).

### 3. Conclusion

In summary, a catalyst based on the new ligand **3** was developed for the Pd-catalyzed cross-coupling of amides and aryl chlorides. This system was much more active than previous catalyst systems that have been used for these reactions, particularly for the coupling

of amides with aryl chlorides bearing an *ortho* substituent. An array of amides were successfully combined with aryl chlorides in good to excellent yields using 1 mol % Pd and with reaction times <5 h.

## 4. Experimental

### 4.1. General reagent information

All reactions were set up in the air and carried out under an atmosphere of argon. Flash chromatography was performed using (a) silica gel from American International Chemical or (b) a Biotage SP4 instrument with prepacked silica cartridges. The *tert*-butanol was purchased from Aldrich Chemical Co. in Sure-Seal bottles and was used as received. Pd(OAc)<sub>2</sub> was a gift from BASF. Aryl halides and amides were purchased from Aldrich Chemical Co., Alfa Aesar, Acros Organics, or Oakwood Products and were used as purchased without further purification. Deionized water was degassed by brief (30 s) sonication under vacuum and then evacuated and backfilled with argon (this procedure was repeated three times). Anhydrous tribasic potassium phosphate was purchased from Fluka Chemical Co., stored in a nitrogen filled glovebox and removed in small quantities and stored on the bench for up to two weeks. Ligands **1**,<sup>5a</sup> **2**,<sup>7</sup> and **4**<sup>3e</sup> were synthesized using literature procedures and ligand **5** was purchased from Strem Chemicals Inc.

### 4.2. General analytical information

Yields refer to isolated yields of compounds greater than 95% purity as determined by gas chromatography (GC) and <sup>1</sup>H NMR. All yields reported in Table 2 are for an average of two experiments. All compounds were characterized by <sup>1</sup>H NMR, <sup>13</sup>C NMR, IR spectroscopy, melting point, and in most cases, elemental analysis. Nuclear Magnetic Resonance spectra were recorded on a Varian 300 MHz instrument or a Bruker 400 MHz instrument. All <sup>1</sup>H NMR experiments are reported in  $\delta$  units, parts per million (ppm), and were measured relative to the solvent residual peak. All <sup>13</sup>C NMR spectra are reported in parts per million relative to solvent residual peak and were obtained with <sup>1</sup>H decoupling. All IR spectra were made on a Perkin–Elmer 2000 FTIR. All GC analyses were performed on an Agilent 6890 gas chromatograph with an FID detector using a J & W DB-1 column (10 m, 0.1 mm I.D.). Elemental analyses were performed by Atlantic Microlabs Inc., Norcross, GA. HRMS spectra were performed on a Bruker APEXIV 4.7t FT-ICR mass spectrometer.

### 4.3. Synthesis of **3**

An oven-dried 300 mL round bottom Schlenk flask, which was equipped with a magnetic stir bar, fitted with a rubber septum, and charged with 2-iodo-2',4',6'-triisopropyl-3,6-dimethoxybiphenyl<sup>7</sup> (3.78 g, 8.11 mmol), was evacuated and backfilled with argon (this process was repeated a total of three times). THF (40 mL) was added via syringe, the reaction mixture was cooled to –78 °C, and *t*-BuLi

(1.7 M in hexane, 9.54 mL, 16.22 mmol) was added in a dropwise fashion over a 20 min period. The solution was stirred for 30 min and then under a positive pressure of argon the septum was removed from the Schlenk flask and anhydrous CuCl (804 mg, 8.11 mmol), which was weighed out in nitrogen filled glovebox, was added rapidly. The flask was refitted with the rubber septum and CIP(*t*-Bu)<sub>2</sub> (1.70 mL, 8.92 mmol) was added in a dropwise fashion over a 10 min period. The reaction mixture was warmed from –78 °C to room temperature at which point the flask was sealed with a Teflon screw cap and heated to 70 °C for 60 h. The solution was cooled to room temperature, diluted with ethyl acetate, washed with aqueous NH<sub>4</sub>OH (this process was repeated a total of three times), washed with brine, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The crude material was recrystallized from hot methanol to yield the desired product as white crystals (2.081 g, 53%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 6.96 (s, 2H), 6.87 (d, *J*=8.7 Hz, 1H), 6.83 (d, *J*=9.0 Hz, 1H), 3.78 (s, 3H), 3.56 (s, 3H), 2.95 (septet, *J*=6.9 Hz, 1H), 2.49 (septet, *J*=6.6 Hz, 2H), 1.32 (d, *J*=6.9 Hz, 6H), 1.21 (d, *J*=6.6 Hz, 6H), 1.14 (s, 9H), 1.10 (s, 9H), 0.93 (d, *J*=6.6 Hz, 6H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ: 155.9, 152.6, 152.5, 147.2, 146.7, 140.5, 140.0, 133.0, 127.6, 127.0, 120.1, 110.9, 108.2, 54.4, 54.0, 34.2, 34.1, 33.8, 32.1, 31.8, 31.3, 25.7, 24.3, 23.6 ppm (observed complexity is due to P–C splitting). <sup>31</sup>P NMR (121 MHz, CDCl<sub>3</sub>) δ: 34.78 ppm. IR (neat, cm<sup>–1</sup>): 2958, 2864, 1581, 1486, 1421, 1250, 1086, 1020, 799, 715. HRMS (ESI) calcd for C<sub>31</sub>H<sub>50</sub>O<sub>2</sub>P [M+H<sup>+</sup>]: 485.3543; found: 485.3537.

#### 4.4. General procedure for Table 2

An oven-dried test tube, which was equipped with a magnetic stir bar and fitted with a Teflon screwcap septum, was charged with Pd(OAc)<sub>2</sub> (1 mol %) and **3** (2.2 mol %). The vessel was evacuated and backfilled with argon (this process was repeated a total of three times) and *t*-BuOH (2.0 mL) and degassed H<sub>2</sub>O (4 mol %) were added via syringe. After addition of the water, the solution was heated to 110 °C for 1.5 min. A second oven-dried test tube, equipped with a magnetic stir bar and fitted with a Teflon screwcap septum, was charged with amide (1.2 mmol) and K<sub>3</sub>PO<sub>4</sub> (1.4 mmol) (aryl chlorides that were solids at room temperature were added with the base). The vessel was evacuated and backfilled with argon (this process was repeated a total of three times) and then the aryl chloride (1.0 mmol) was added via syringe and the activated catalyst solution was transferred from the first reaction vessel into the second via cannula. The solution was heated to 110 °C until the aryl chloride had been completely consumed as judged by GC analysis. The reaction mixture was then cooled to room temperature, diluted with ethyl acetate, and washed with water. The layers were separated and the organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was purified via flash chromatography on silica gel.

#### 4.5. *N*-*o*-Tolylacetamide<sup>5a</sup> (Table 2, entry 1)

Following the general procedure, a mixture of 2-chlorotoluene (117 μL, 1.0 mmol), acetamide (71 mg, 1.2 mmol), K<sub>3</sub>PO<sub>4</sub> (297 mg, 1.4 mmol), Pd(OAc)<sub>2</sub> (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol), H<sub>2</sub>O (0.7 μL, 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 40 min. The crude product was purified by flash chromatography on silica gel (40% hexanes in EtOAc) to provide the title compound as a white solid (119 mg, 80%). Mp=108–109 °C (lit. 108–109). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.68 (d, *J*=7.8 Hz, 1H), 7.23–7.15 (m, 3H), 7.07 (t, *J*=7.5 Hz, 1H), 2.23 (s, 3H), 2.17 (s, 3H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ: 168.8, 135.7, 130.5, 130.1, 126.6, 125.5, 124.0, 24.1, 17.9 ppm. IR (neat, cm<sup>–1</sup>): 3290, 3028, 2981, 1654, 1588, 1531, 1486, 1460, 1369, 1288, 1272, 1118, 1039, 1018, 756, 714, 700, 653, 608, 562, 534, 446. Anal. Calcd for C<sub>9</sub>H<sub>11</sub>NO: C, 72.46; H, 7.43. Found: C, 72.25; H, 7.59.

#### 4.6. *N*-(2-Ethylphenyl)acetamide<sup>14</sup> (Table 2, entry 2)

Following the general procedure, a mixture of 1-chloro-2-ethylbenzene (132 μL, 1.0 mmol), acetamide (71 mg, 1.2 mmol), K<sub>3</sub>PO<sub>4</sub> (297 mg, 1.4 mmol), Pd(OAc)<sub>2</sub> (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol), H<sub>2</sub>O (0.7 μL, 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 1.5 h. The crude product was purified by flash chromatography on silica gel (50% EtOAc in hexanes) to provide the title compound as a white solid (129 mg, 79%). Mp=115–116 °C (lit. 111–111.8 °C). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.63 (d, *J*=7.2 Hz, 1H), 7.33 (br s, 1H), 7.21–7.10 (m, 3H), 2.57 (q, *J*=7.5 Hz, 2H), 2.15 (s, 3H), 1.20 (t, *J*=7.8 Hz, 3H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ: 168.9, 136.0, 135.0, 128.6, 126.6, 125.9, 124.6, 24.27, 24.19, 14.0 ppm. IR (neat, cm<sup>–1</sup>): 3271, 3037, 2964, 2929, 2869, 1653, 1588, 1540, 1448, 1373, 1296, 1053, 1018, 971, 749, 717, 610, 487. HRMS (ESI) calcd for C<sub>10</sub>H<sub>14</sub>NO [M+H<sup>+</sup>]: 164.1070; found: 164.1077.

#### 4.7. *N*-(2-Methoxyphenyl)acetamide<sup>5a</sup> (Table 2, entry 3)

Following the general procedure, a mixture of 2-chloroanisole (127 μL, 1.0 mmol), acetamide (71 mg, 1.2 mmol), K<sub>3</sub>PO<sub>4</sub> (297 mg, 1.4 mmol), Pd(OAc)<sub>2</sub> (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol), H<sub>2</sub>O (0.7 μL, 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 3 h. The crude product was purified by flash chromatography on silica gel (40% EtOAc in hexanes) to provide the title compound as a white solid (150 mg, 91%). Mp=87–88 °C (lit. 87–88). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 8.35 (dd, *J*=8.1, 1.7 Hz, 1H), 7.78 (br s, 1H), 7.03 (td, *J*=7.5, 1.8 Hz, 1H), 6.95 (td, *J*=7.8, 1.5 Hz, 1H), 6.86 (dd, *J*=8.1, 1.5 Hz, 1H), 3.87 (s, 3H), 2.19 (s, 3H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ: 168.3, 147.7, 127.8, 123.7, 121.1, 119.8, 109.9, 55.7, 25.0 ppm. IR (neat, cm<sup>–1</sup>): 3249, 3195, 3137, 3063, 3021, 2964, 1659, 1596, 1544, 1496, 1468, 1459, 1436, 1368, 1323, 1291, 1272, 1252, 1025, 751. Anal. Calcd for C<sub>9</sub>H<sub>11</sub>NO<sub>2</sub>: C, 65.44; H, 6.71. Found: C, 65.89; H, 6.90.

#### 4.8. *N*-(2,5-Dimethylphenyl)benzamide (Table 2, entry 4)

Following the general procedure, a mixture of 2-chloro-*p*-xylene (133 μL, 1.0 mmol), benzamide (145 mg, 1.2 mmol), K<sub>3</sub>PO<sub>4</sub> (297 mg, 1.4 mmol), Pd(OAc)<sub>2</sub> (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol), H<sub>2</sub>O (0.7 μL, 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 3 h. The crude product was purified by flash chromatography on silica gel (20% EtOAc in hexanes) to provide the title compound as a white solid (215 mg, 95%). Mp=151–152 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 7.88 (dt, *J*=6.6, 1.5 Hz, 2H), 7.78 (s, 1H), 7.71 (br s, 1H), 7.56 (tt, *J*=6.9, 1.8 Hz, 1H), 7.49 (tt, *J*=6.6, 1.5 Hz, 2H), 7.11 (d, *J*=7.8 Hz, 1H), 6.94 (dd, *J*=7.5, 0.9 Hz, 1H), 2.34 (s, 3H), 2.28 (s, 3H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ: 136.7, 135.6, 135.1, 131.9, 130.43, 130.41, 128.9, 127.1, 126.2, 123.8, 21.3, 17.5 ppm. IR (neat, cm<sup>–1</sup>): 3253, 2922, 1644, 1618, 1580, 1530, 1489, 1501, 1308, 1290, 1029, 875, 808, 708, 602, 450. Anal. Calcd for C<sub>15</sub>H<sub>15</sub>NO: C, 79.97; H, 6.71. Found: C, 79.81; H, 6.78.

#### 4.9. *N*-(2,5-Dimethoxyphenyl)benzamide<sup>15</sup> (Table 2, entry 5)

Following the general procedure, a mixture of 2,5-dimethoxychlorobenzene (143 μL, 1.0 mmol), benzamide (145 mg, 1.2 mmol), K<sub>3</sub>PO<sub>4</sub> (297 mg, 1.4 mmol), Pd(OAc)<sub>2</sub> (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol), H<sub>2</sub>O (0.7 μL, 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 1.5 h. The crude product was purified by flash chromatography on silica gel (10% EtOAc in hexanes) to provide the title compound as a white-tan solid (242 mg, 94%). Mp=87–88 °C (lit. 82–84 °C). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ: 8.60 (br s, 1H), 8.30 (d, *J*=3.0 Hz, 1H), 7.89 (dt, *J*=6.6, 1.8 Hz, 2H), 7.58–7.46 (m, 3H), 6.83 (d, *J*=9.0 Hz, 1H), 6.61 (dd, *J*=9.0, 3.0 Hz, 1H), 3.87 (s, 3H), 3.82 (s, 3H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ: 165.3, 154.0, 142.4, 135.2, 131.9, 128.9, 128.5, 127.1, 110.7, 108.9, 105.9, 56.3,



55.9 ppm. IR (neat,  $\text{cm}^{-1}$ ): 3427, 3335, 3057, 3000, 2937, 2955, 2833, 1668, 1601, 1532, 1498, 1478, 1464, 1423, 1268, 1220, 1202, 1179, 1164, 1047, 1024, 862, 797, 704, 679. Anal. Calcd for  $\text{C}_{15}\text{H}_{15}\text{NO}_3$ : C, 70.02; H, 5.88. Found: C, 69.89; H, 6.03.

#### 4.10. *N-p-Tolyl-4-(trifluoromethyl)benzamide*<sup>16</sup> (Table 2, entry 6)

Following the general procedure, a mixture of 4-chlorotoluene (118  $\mu\text{L}$ , 1.0 mmol), 4-trifluoromethylbenzamide (227 mg, 1.2 mmol),  $\text{K}_3\text{PO}_4$  (297 mg, 1.4 mmol),  $\text{Pd}(\text{OAc})_2$  (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol),  $\text{H}_2\text{O}$  (0.7  $\mu\text{L}$ , 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 2 h. The crude product was dissolved in acetone, evaporated on to a small amount of silica gel, and purified by flash chromatography on silica gel (gradient eluent: 10–30% EtOAc in hexanes) to provide the title compound as a white solid (222 mg, 80%). Mp=235–236 °C (lit. 236–238 °C).  $^1\text{H}$  NMR (300 MHz,  $(\text{CD}_3)_2\text{SO}$ )  $\delta$ : 10.4 (s, 1H), 8.14 (d,  $J=7.8$  Hz, 2H), 7.90 (d,  $J=8.4$  Hz, 2H), 7.66 (dd,  $J=8.4$  Hz, 2H), 7.17 (d,  $J=8.1$  Hz, 2H), 2.28 (s, 3H) ppm.  $^{13}\text{C}$  NMR (75 MHz,  $(\text{CD}_3)_2\text{SO}$ )  $\delta$ : 164.2, 138.9, 136.4, 133.1, 131.5, 131.1, 129.5, 129.1, 128.6, 125.8, 125.4, 125.4, 120.5, 20.5 ppm (complexity is due to  $\text{CF}_3$ -group). IR (neat,  $\text{cm}^{-1}$ ): 3333, 2919, 1649, 1599, 1580, 1530, 1407, 1160, 1125, 861, 815, 770. Anal. Calcd for  $\text{C}_{15}\text{H}_{12}\text{F}_3\text{NO}$ : C, 64.51; H, 4.33. Found: C, 65.00; H, 4.68.

#### 4.11. Methyl 3-(cyclopropanecarboxamido)benzoate (Table 2, entry 7)

Following the general procedure, a mixture of methyl 3-chlorobenzoate (139  $\mu\text{L}$ , 1.0 mmol), cyclopropanecarboxamide (102 mg, 1.2 mmol),  $\text{K}_3\text{PO}_4$  (297 mg, 1.4 mmol),  $\text{Pd}(\text{OAc})_2$  (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol),  $\text{H}_2\text{O}$  (0.7  $\mu\text{L}$ , 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 5 h. The crude product was purified by flash chromatography on silica gel (gradient eluent: 20–30% EtOAc in hexanes) to provide the title compound as a white solid (169 mg, 77%). Mp=129–130 °C.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 8.10–8.07 (m, 2H), 7.86 (d,  $J=7.8$  Hz, 1H), 7.74 (d,  $J=7.8$  Hz, 1H), 7.35 (t,  $J=8.1$  Hz, 1H), 3.87 (s, 3H), 1.55 (sep,  $J=3.9$  Hz, 1H), 1.08 (dt,  $J=6.9$ , 3.9 Hz, 2H), 0.85–0.79 (m, 2H) ppm.  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 172.6, 167.0, 138.5, 130.8, 129.2, 125.1, 124.4, 120.7, 52.4, 15.7, 8.3 ppm. IR (neat,  $\text{cm}^{-1}$ ): 3294, 3013, 2952, 1724, 1663, 1596, 1548, 1488, 1431, 1395, 1302, 1273, 1241, 1197, 1178, 1107, 1082, 956, 755, 688. Anal. Calcd for  $\text{C}_{12}\text{H}_{13}\text{NO}_3$ : C, 65.74; H, 5.98. Found: C, 65.47; H, 6.10.

#### 4.12. *N*-(2-Methoxyphenyl)furan-2-carboxamide (Table 2, entry 8)

Following general procedure A, a mixture of 2-chloroanisole (127  $\mu\text{L}$ , 1.0 mmol), 2-furamide (133 mg, 1.2 mmol),  $\text{K}_3\text{PO}_4$  (297 mg, 1.4 mmol),  $\text{Pd}(\text{OAc})_2$  (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol),  $\text{H}_2\text{O}$  (0.7  $\mu\text{L}$ , 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 2 h. The crude product was purified by flash chromatography on silica gel (10% EtOAc in hexanes) to provide the title compound as a white solid (208 mg, 96%). Mp=123–124 °C.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 8.78 (br s, 1H), 8.50 (dd,  $J=7.8$ , 1.8 Hz, 1H), 7.52 (dd,  $J=1.5$ , 0.6 Hz, 1H), 7.22 (dd,  $J=3.6$ , 0.9 Hz, 1H), 7.08 (td,  $J=7.8$ , 1.8 Hz, 1H), 7.00 (tdd,  $J=7.7$ , 1.5, 0.3 Hz, 1H), 6.91 (dd,  $J=8.1$ , 1.5 Hz, 1H), 6.54 (dd,  $J=3.6$ , 1.8 Hz, 1H), 3.93 (s, 3H) ppm.  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 156.0, 148.3, 148.1, 144.28, 144.26, 127.3, 124.0, 121.2, 119.8, 115.03, 114.98, 112.57, 112.53, 110.0, 55.9 ppm (complexity of  $^{13}\text{C}$  NMR data is due to detection of rotamers). IR (neat,  $\text{cm}^{-1}$ ): 3410, 3141, 3118, 3019, 2979, 2943, 2843, 1672, 1606, 1584, 1534, 1524, 1462, 1437, 1251, 1226, 1216, 1105, 1020, 1012, 765, 750, 653, 604, 593. Anal. Calcd for  $\text{C}_{12}\text{H}_{11}\text{NO}_3$ : C, 66.35; H, 5.10. Found: C, 66.16; H, 5.19.

#### 4.13. *N*-(2-Ethylphenyl)nicotinamide (Table 2, entry 9)

Following the general procedure, a mixture of 1-chloro-2-ethylbenzene (132  $\mu\text{L}$ , 1.0 mmol), nicotinamide (147 mg, 1.2 mmol),  $\text{K}_3\text{PO}_4$  (297 mg, 1.4 mmol),  $\text{Pd}(\text{OAc})_2$  (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol),  $\text{H}_2\text{O}$  (0.7  $\mu\text{L}$ , 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 3 h. The crude product was purified by flash chromatography on silica gel (80% EtOAc in hexanes) to provide the title compound as a white solid (189 mg, 83%). Mp=101–102.5 °C.  $^1\text{H}$  NMR (300 MHz,  $(\text{CD}_3)_2\text{SO}$ )  $\delta$ : 10.1 (s, 1H), 9.13 (d,  $J=2.1$  Hz, 1H), 8.77 (dd,  $J=4.8$ , 1.2 Hz, 1H), 8.31 (d,  $J=7.8$  Hz, 1H), 7.58 (dd,  $J=8.1$ , 4.8 Hz, 1H), 7.33–7.23 (m, 4H), 2.63 (q,  $J=7.8$  Hz, 2H), 1.13 (t,  $J=7.8$  Hz, 3H) ppm.  $^{13}\text{C}$  NMR (75 MHz,  $(\text{CD}_3)_2\text{SO}$ )  $\delta$ : 164.3, 152.2, 148.7, 139.9, 135.4, 130.1, 128.6, 127.6, 126.8, 126.2, 123.6, 24.0, 14.2 ppm. IR (neat,  $\text{cm}^{-1}$ ): 3262, 3035, 2968, 2934, 2875, 1651, 1591, 1525, 1491, 1473, 1452, 1418, 1306, 1275, 1026, 759, 749, 706. HRMS (ESI) calcd for  $\text{C}_{14}\text{H}_{15}\text{N}_2\text{O}$  [ $\text{M}+\text{H}^+$ ]: 227.1179; found: 227.1176.

#### 4.14. *N*-(4-Methoxyphenyl)-2-(thiophen-2-yl)acetamide (Table 2, entry 10)

Following the general procedure, a mixture of 4-chloroanisole (122  $\mu\text{L}$ , 1.0 mmol), 2-thiopheneacetamide (169 mg, 1.2 mmol),  $\text{K}_3\text{PO}_4$  (297 mg, 1.4 mmol),  $\text{Pd}(\text{OAc})_2$  (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol),  $\text{H}_2\text{O}$  (0.7  $\mu\text{L}$ , 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 1.5 h. The crude product was purified via the Biotage SP4 (silica-packed 25+M; 0–100% EtOAc/hexanes) to provide the title compound as a pale yellow solid (223 mg, 90%). Mp=122–123 °C.  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{CN}$ )  $\delta$ : 8.35 (br s, 1H), 7.43 (dt,  $J=9.0$ , 3.4 Hz, 2H), 7.29 (dd,  $J=4.4$ , 2.0 Hz, 1H), 6.99–6.97 (m, 2H), 6.86 (dt,  $J=9.0$ , 3.3 Hz, 2H), 3.82 (s, 2H), 3.75 (s, 3H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $\text{CD}_3\text{CN}$ )  $\delta$ : 168.9, 157.1, 138.1, 132.7, 127.7, 127.6, 125.9, 122.3, 114.8, 55.9, 38.4. IR (neat,  $\text{cm}^{-1}$ ): 3329, 3106, 2960, 2834, 1659, 1609, 1544, 1511, 1454, 1407, 1310, 1242, 1173, 1025, 831, 702. HRMS (ESI) calcd for  $\text{C}_{13}\text{H}_{14}\text{NO}_2\text{S}$  [ $\text{M}+\text{H}^+$ ]: 248.0740; found: 248.0740.

#### 4.15. *N*-(2-Ethylphenyl)-2-(thiophen-2-yl)acetamide (Table 2, entry 11)

Following the general procedure, a mixture of 1-chloro-2-ethylbenzene (132  $\mu\text{L}$ , 1.0 mmol), 2-thiopheneacetamide (169 mg, 1.2 mmol),  $\text{K}_3\text{PO}_4$  (297 mg, 1.4 mmol),  $\text{Pd}(\text{OAc})_2$  (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol),  $\text{H}_2\text{O}$  (0.7  $\mu\text{L}$ , 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 3 h. The crude product was purified by flash chromatography on silica gel (20% EtOAc in hexanes) to provide the title compound as a white solid (207 mg, 84%). Mp=120.5–121.5 °C.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 7.92 (d,  $J=7.8$  Hz, 1H), 7.35–7.33 (m, 1H), 7.20 (td,  $J=8.1$ , 2.1 Hz, 1H), 7.14–7.05 (m, 4H), 3.99 (s, 3H), 2.31 (q,  $J=7.5$  Hz, 2H), 0.99 (t,  $J=7.5$  Hz, 3H) ppm.  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 168.0, 136.0, 134.8, 134.3, 128.8, 128.2, 127.8, 126.9, 126.4, 125.4, 122.6, 38.5, 24.5, 14.1 ppm. IR (neat,  $\text{cm}^{-1}$ ): 3257, 3034, 2963, 2930, 2871, 1655, 1585, 1532, 1447, 1405, 1342, 1256, 967, 752, 689. HRMS (ESI) calcd for  $\text{C}_{14}\text{H}_{16}\text{NOS}$  [ $\text{M}+\text{H}^+$ ]: 246.0947; found: 246.0949.

#### 4.16. Methyl 3-(furan-2-carboxamido)benzoate (Table 2, entry 12)

Following the general procedure, a mixture of methyl 3-chlorobenzoate (139  $\mu\text{L}$ , 1.0 mmol), 2-furamide (133 mg, 1.2 mmol),  $\text{K}_3\text{PO}_4$  (297 mg, 1.4 mmol),  $\text{Pd}(\text{OAc})_2$  (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol),  $\text{H}_2\text{O}$  (0.7  $\mu\text{L}$ , 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 1.5 h. The crude product was purified by flash chromatography on silica gel (30% EtOAc in hexanes) to provide the title compound as a white solid (237 mg, 97%). Mp=83–85 °C.  $^1\text{H}$

NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 8.39 (br s, 1H), 8.19 (t,  $J=1.8$  Hz, 1H), 8.02 (ddd,  $J=8.1, 2.4, 1.2$  Hz, 1H), 7.78 (ddd,  $J=7.8, 1.5, 0.9$  Hz, 1H), 7.45 (dd,  $J=1.8, 0.8$  Hz, 1H), 7.39 (t,  $J=8.1$  Hz, 1H), 7.21 (dd,  $J=4.2, 0.8$  Hz, 1H), 6.51 (dd,  $J=3.6, 1.8$  Hz, 1H), 3.87 (s, 3H) ppm.  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 166.7, 156.3, 147.5, 144.54, 144.51, 137.7, 130.9, 129.3, 125.5, 124.5, 120.9, 115.7, 115.6, 112.71, 112.67, 52.3 ppm (complexity of  $^{13}\text{C}$  NMR data is due to detection of rotamers). IR (neat,  $\text{cm}^{-1}$ ): 3325, 3130, 2952, 2845, 1722, 1668, 1598, 1583, 1542, 1489, 1473, 1441, 1323, 1294, 1265, 1230, 1165, 1118, 1083, 1012, 884, 755, 684, 594. HRMS (ESI) calcd for  $\text{C}_{13}\text{H}_{12}\text{NO}_4$  [ $\text{M}+\text{H}^+$ ]: 246.0761; found: 246.0771.

#### 4.17. *N*-(4-Methoxyphenyl)nicotinamide (Table 2, entry 13)

Following the general procedure, a mixture of 4-chloroanisole (122  $\mu\text{L}$ , 1.0 mmol), nicotinamide (147 mg, 1.2 mmol),  $\text{K}_3\text{PO}_4$  (297 mg, 1.4 mmol),  $\text{Pd}(\text{OAc})_2$  (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol),  $\text{H}_2\text{O}$  (0.7  $\mu\text{L}$ , 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 5 h. The crude product was purified by flash chromatography on silica gel with EtOAc as eluent to provide the title compound as a white solid (192 mg, 84%). Mp=152–154 °C.  $^1\text{H}$  NMR (300 MHz,  $(\text{CD}_3)_2\text{SO}$ )  $\delta$ : 10.3 (s, 1H), 9.11 (dd,  $J=2.1, 0.8$  Hz, 1H), 8.75 (dd,  $J=4.8, 1.5$  Hz, 1H), 8.28 (ddd,  $J=7.8, 2.1, 1.5$  Hz, 1H), 7.69 (d,  $J=9.0$  Hz, 2H), 7.55 (ddd,  $J=7.8, 4.8, 0.9$  Hz, 1H), 6.95 (d,  $J=9.0$  Hz, 2H), 3.75 (s, 3H) ppm.  $^{13}\text{C}$  NMR (75 MHz,  $(\text{CD}_3)_2\text{SO}$ )  $\delta$ : 163.6, 155.8, 152.0, 148.7, 135.4, 131.9, 130.7, 123.5, 122.0, 113.8, 55.2 ppm. IR (neat,  $\text{cm}^{-1}$ ): 3321, 3010, 2952, 2838, 1672, 1643, 1614, 1546, 1510, 1485, 1423, 1409, 1276, 1248, 1177, 1124, 1030, 824, 706. Anal. Calcd for  $\text{C}_{13}\text{H}_{12}\text{N}_2\text{O}_2$ : C, 68.41; H, 5.30. Found: C, 67.86; H, 5.26.

#### 4.18. *N*-Phenyl-2-(pyridin-2-yl)acetamide (Table 2, entry 14)

Following the general procedure, a mixture of chlorobenzene (102  $\mu\text{L}$ , 1.0 mmol), pyridine-2-acetamide (163 mg, 1.2 mmol),  $\text{K}_3\text{PO}_4$  (297 mg, 1.4 mmol),  $\text{Pd}(\text{OAc})_2$  (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol),  $\text{H}_2\text{O}$  (0.7  $\mu\text{L}$ , 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 4 h. The crude product was purified via the Biotage SP4 (silica-packed 25+M; 0–100% EtOAc/hexanes) to provide the title compound as a white solid (178 mg, 84%). Mp=135–136 °C.  $^1\text{H}$  NMR (400 MHz,  $(\text{CD}_3)_2\text{SO}$ )  $\delta$ : 10.3 (s, 1H), 8.45 (d,  $J=4.4$  Hz, 1H), 7.75 (td,  $J=7.6, 1.8$  Hz, 1H), 7.62 (d,  $J=7.7$  Hz, 2H), 7.40 (d,  $J=7.8$  Hz, 1H), 7.32–7.25 (m, 3H), 7.04 (t,  $J=7.4$  Hz, 1H), 3.85 (s, 2H) ppm.  $^{13}\text{C}$  NMR (100 MHz,  $(\text{CD}_3)_2\text{SO}$ )  $\delta$ : 168.2, 156.1, 149.0, 139.2, 136.6, 128.7, 124.0, 123.2, 121.9, 119.1, 45.9. IR (neat,  $\text{cm}^{-1}$ ): 3228, 3185, 3011, 2973, 1676, 1593, 1545, 1496, 1476, 1444, 1343, 1326, 1274, 1209, 1150, 1002, 780, 747, 685. HRMS (ESI) calcd for  $\text{C}_{13}\text{H}_{13}\text{N}_2\text{O}$  [ $\text{M}+\text{H}^+$ ]: 213.1022; found: 213.1025.

#### 4.19. *N*-(Pyridin-3-yl)cyclohexanecarboxamide<sup>17</sup> (Table 2, entry 15)

Following the general procedure, a mixture of 3-chloropyridine (95  $\mu\text{L}$ , 1.0 mmol), cyclohexanecarboxamide (153 mg, 1.2 mmol),  $\text{K}_3\text{PO}_4$  (297 mg, 1.4 mmol),  $\text{Pd}(\text{OAc})_2$  (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol),  $\text{H}_2\text{O}$  (0.7  $\mu\text{L}$ , 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 12 h. The crude product was purified by flash chromatography on silica gel with EtOAc as eluent followed by a second purification via the Biotage SP4 (silica-packed 25+M; 70–100% EtOAc in hexanes) to provide the title compound as a white solid (133 mg, 65%). Mp=128.5–130.5 °C (lit. 134–135 °C).  $^1\text{H}$  NMR (300 MHz,  $(\text{CD}_3)_2\text{SO}$ )  $\delta$ : 10.0 (s, 1H), 8.75 (d,  $J=2.4$  Hz, 1H), 8.22 (dd,  $J=4.8, 1.5$  Hz, 1H), 8.05 (dt,  $J=8.4, 1.8$  Hz, 1H), 7.30 (dd,  $J=8.1, 1.5$  Hz, 1H), 2.34 (tt,  $J=11.4, 3.3$  Hz, 1H), 1.82–1.62 (m, 5H), 1.46–1.14 (m, 5H) ppm.  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$ : 174.9, 143.9, 140.7, 136.1, 125.9, 123.5, 44.8, 29.1, 25.4, 25.2 ppm. IR (neat,  $\text{cm}^{-1}$ ): 3299, 3180, 3121, 3047, 2931, 2855, 1667, 1600, 1587, 1543, 1483, 1450, 1422,

1335, 1278, 1196, 1173, 1131, 949, 896, 804, 761, 707, 635. HRMS (ESI) calcd for  $\text{C}_{12}\text{H}_{17}\text{N}_2\text{O}$  [ $\text{M}+\text{H}^+$ ]: 205.1335; found: 205.1326.

#### 4.20. *N*-(Pyridin-3-yl)furan-2-carboxamide (Table 2, entry 16)

Following general procedure A, a mixture of 3-chloropyridine (95  $\mu\text{L}$ , 1.0 mmol), 2-furamide (133 mg, 1.2 mmol),  $\text{K}_3\text{PO}_4$  (297 mg, 1.4 mmol),  $\text{Pd}(\text{OAc})_2$  (2.3 mg, 0.010 mmol), **3** (11 mg, 0.022 mmol),  $\text{H}_2\text{O}$  (0.7  $\mu\text{L}$ , 0.04 mmol), and *t*-BuOH (2.0 mL) was heated to 110 °C for 1.5 h. The crude product was purified by flash chromatography on silica gel (gradient eluent: 50–100% EtOAc in  $\text{CH}_2\text{Cl}_2$ ) to provide the title compound as a white-tan solid (181 mg, 96%). Mp=142–143 °C.  $^1\text{H}$  NMR (300 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$ : 8.88 (dd,  $J=2.4, 0.8$  Hz, 1H), 8.27 (dd,  $J=4.5, 1.4$  Hz, 1H), 8.22 (ddd,  $J=8.4, 2.4, 1.5$  Hz, 1H), 7.74 (dd,  $J=1.8, 0.9$  Hz, 1H), 7.41 (ddd,  $J=8.4, 4.8, 0.6$  Hz, 1H), 7.29 (dd,  $J=3.6, 0.8$  Hz, 1H), 6.63 (dd,  $J=3.5, 1.7$  Hz, 1H) ppm.  $^{13}\text{C}$  NMR (75 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$ : 159.0, 148.5, 147.0, 145.5, 142.6, 137.0, 129.8, 125.2, 116.8, 113.4 ppm. IR (neat,  $\text{cm}^{-1}$ ): 3248, 3118, 3044, 1670, 1601, 1578, 1538, 1483, 1470, 1423, 1332, 1298, 1229, 1167, 1012, 884, 802, 756, 706, 595. HRMS (ESI) calcd for  $\text{C}_{10}\text{H}_9\text{N}_2\text{O}_2$  [ $\text{M}+\text{H}^+$ ]: 189.0659; found: 189.0661.

#### Acknowledgements

We thank the National Institutes of Health (NIH) for financial support of this project (Grant GM-58160). We thank Merck, BASF (Pd compounds), Chemetall ( $\text{Cs}_2\text{CO}_3$ ), and Nippon Chemical for additional support. B.P.F. thanks the William Asbornsen Albert Memorial Fund for a fellowship. K.D. thanks the Department of Chemistry and the Interdisciplinary Nanoscience Center, University of Aarhus for funding. Q.Z. thanks the China Scholarship Council and the National Science Foundation of China (Grant No. 20672088) for financial support. The Varian NMR instrument used was supported by the NSF (Grants CHE 9808061 and DBI 9729592).

#### Supplementary data

Supplementary data associated with this article can be found in the online version, at doi:10.1016/j.tet.2009.04.096.

#### References and notes

- (a) Lindley, J. *Tetrahedron* **1984**, *40*, 1433; (b) Goldberg, I. *Chem. Ber.* **1906**, *39*, 1691.
- (a) Strieter, E. R.; Bhayana, B.; Buchwald, S. L. *J. Am. Chem. Soc.* **2009**, *131*, 78; (b) Ma, D.; Cai, Q. *Acc. Chem. Res.* **2008**, *41*, 1450; (c) Ley, S. V.; Thomas, A. W. *Angew. Chem., Int. Ed.* **2003**, *42*, 5400; (d) Kunz, K.; Scholz, U.; Ganzer, D. *Synlett* **2003**, 2428; (e) Klapars, A.; Huang, X.; Buchwald, S. L. *J. Am. Chem. Soc.* **2002**, *124*, 7421; (f) Klapars, A.; Antilla, J. C.; Huang, X.; Buchwald, S. L. *J. Am. Chem. Soc.* **2001**, *123*, 7727.
- (a) Imbriglio, J. E.; DiRocco, D.; Raghavan, S.; Ball, R. G.; Tsou, N.; Mosley, R. T.; Tata, T. R.; Colletti, S. L. *Tetrahedron Lett.* **2008**, *49*, 4897; (b) Klapars, A.; Campos, K. R.; Chen, C.; Volante, R. P. *Org. Lett.* **2005**, *7*, 1185; (c) Willis, M. C.; Brace, G. N.; Holmes, I. P. *Synlett* **2005**, 3229; (d) Wallace, J. W.; Klauber, D. J.; Chen, C.; Volante, R. P. *Org. Lett.* **2003**, *5*, 4749; (e) Huang, X.; Anderson, K. W.; Zim, D.; Jiang, L.; Klapars, A.; Buchwald, S. L. *J. Am. Chem. Soc.* **2003**, *125*, 6653.
- (a) Shen, Q.; Hartwig, J. F. *J. Am. Chem. Soc.* **2007**, *129*, 7734; (b) McLaughlin, M.; Palucki, M.; Davies, I. W. *Org. Lett.* **2006**, *8*, 3311; (c) Shi, F.; Smith, M. R.; Maleczka, R. E. *Org. Lett.* **2006**, *8*, 1411; (d) Yin, J.; Buchwald, S. L. *J. Am. Chem. Soc.* **2002**, *124*, 6043; (e) Hartwig, J. F.; Kawatsura, M.; Hauck, S. I.; Shaughnessy, K. H.; Alcazar-Roman, L. M. *J. Org. Chem.* **1999**, *64*, 5575.
- (a) Ikawa, T.; Barder, T. E.; Biscoe, M. R.; Buchwald, S. L. *J. Am. Chem. Soc.* **2007**, *129*, 13001; (b) Shen, Q.; Shekhar, S.; Stambuli, J. P.; Hartwig, J. F. *Angew. Chem., Int. Ed.* **2005**, *44*, 1371; (c) Ghosh, A.; Sieser, J. E.; Riou, M.; Cai, W.; Rivera-Ruiz, L. *Org. Lett.* **2003**, *5*, 2207.
- (a) Nodwell, M.; Pereira, A.; Riffell, J. L.; Zimmerman, C.; Patrick, B. O.; Roberge, M.; Anderson, R. J. *J. Org. Chem.* **2009**, *74*, 995; (b) Surry, D. S.; Buchwald, S. L. *Angew. Chem., Int. Ed.* **2008**, *47*, 6338; (c) Li, X.; Vince, R. *Bioorg. Med. Chem.* **2006**, *14*, 5742; (d) Bringmann, G.; Gulder, T.; Reichert, M.; Meyer, F. *Org. Lett.* **2006**, *8*, 1037.
- Barder, T. E.; Buchwald, S. L. *J. Am. Chem. Soc.* **2007**, *129*, 12003.
- Fors, B. P.; Watson, D. W.; Biscoe, M. R.; Buchwald, S. L. *J. Am. Chem. Soc.* **2008**, *130*, 13552.
- Fors, B. P.; Krattiger, P.; Strieter, E.; Buchwald, S. L. *Org. Lett.* **2008**, *10*, 3505.

10. (a) Fairlamb, I. J. S.; Kapdi, A. R.; Lee, A. F.; McGlacken, G. P.; Weissburger, F.; de Vries, A. H. M.; de Vondervoort, L. S. *Chem.—Eur. J.* **2006**, *12*, 8750; (b) Mace, Y.; Kapdi, A. R.; Fairlamb, I. J. S.; Jutand, A. *Organometallics* **2006**, *14*, 1818; (c) Amatore, C.; Jutand, A. *Coord. Chem. Rev.* **1998**, *178–180*, 511.
11. Pd(II) salts must be reduced in situ to form the active Pd(0) catalyst. For examples, see: (a) Denmark, S. E.; Smith, R. C. *Synlett* **2006**, 2921; (b) Viciu, M. S.; Germaineau, R. F.; Navarro-Fernandez, O.; Stevens, E. D.; Nolan, S. P. *Organometallics* **2002**, *21*, 5470; (c) Trzeciak, A. M.; Ciunik, Z.; Ziolkowski, J. J. *Organometallics* **2002**, *21*, 132; (d) Amatore, C.; Jutand, A.; M'Barki, M. A. *Organometallics* **1992**, *11*, 3009.
12. K<sub>3</sub>PO<sub>4</sub> was used for the remainder of the paper due to its lower cost than carbonate bases.
13. Anderson, K. W.; Tundel, R. E.; Ikawa, T.; Altman, R. A.; Buchwald, S. L. *Angew. Chem., Int. Ed.* **2006**, *45*, 6523.
14. Hansch, C. J. *Org. Chem.* **1955**, *20*, 10266.
15. Lyon, M. A.; Lawrence, S.; Williams, D. J.; Jackson, Y. A. *J. Chem. Soc., Perkin Trans. 1* **1999**, 437.
16. Zhang, Z.; Yu, Y.; Liebeskind, L. S. *Org. Lett.* **2008**, *10*, 3005.
17. Barton, D. H. R.; Ozbalik, N.; Vacher, B. *Tetrahedron* **1988**, *44*, 3501.